Big Move For Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ) jumped higher at $6.27, representing a gain of 35.7%. On Tue 26 Nov 19, HEPA:NASDAQ hit a New 2-Week High of $4.62. The stock got featured on our News Catalysts scanner on Thu 21 Nov 19 at 08:55 AM in the 'BIOTECH' category. From Wed 06 Nov 19, the stock recorded 50.00% Up Days and 40.00% Green Days
About Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ)
ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.
Top 10 Gainers:
- Paringa Resources Limited (PNRL:NASDAQ), 266.2%
- ASLAN Pharmaceuticals Limited (ASLN:NASDAQ), 81.25%
- BIO-key International, Inc. (BKYI:NASDAQ), 39.75%
- AVX Corporation (AVX:NYSE), 36.37%
- Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ), 35.71%
- Onconova Therapeutics, Inc. (ONTX:NASDAQ), 33.87%
- Sequans Communications S.A. (SQNS:NYSE), 28.35%
- GTT Communications, Inc. (GTT:NYSE), 25.66%
- Summit Wireless Technologies, Inc. (WISA:NASDAQ), 22.54%
- Zosano Pharma Corporation (ZSAN:NASDAQ), 22.37%